To further explore the role of AKT and its downstream signaling pathway in Shp2-induced drug resistance in SCLC, we examined the expression of relevant members of the AKT downstream pathway in SCLC cell lines with induced or inhibited Shp2 expression with or without cisplatin treatment. This evidence concerns the gene PTPN11 and small cell lung carcinoma.